This trial is expected to begin following completion of the current phase I/II trial. To date, Advaxis has completed enrollment and dosing of the first two of four cohorts consisting of patients with cervical cancer. Review by an independent safety panel has found that this assessment of the modified listeria-based live vaccine is safe. The primary endpoint of the Advaxis’ current phase I/II is to establish a maximal safe dose of Lovaxin C.
Additionally, upon the completion of the phase I/II Lovaxin C clinical trial, Advaxis expects to continue its program in cervical cancer and diseases related to the human papilloma virus (HPV), as well as other clinical programs addressing areas such as breast cancer in parallel with the Gynecologic Oncology Group program, when finalized.
“Our collaboration with this excellent research group will enable us to objectively demonstrate the therapeutic efficacy of our Lovaxin C vaccine for the treatment of women with cervical cancer,” said Dr John Rothman, vice president of Clinical Development for Advaxis
Unlike current products on the market, which are ineffective in women already infected with HPV, which causes cervical cancer, Lovaxin C is designed to treat women who have already developed cervical cancer as a result of the HPV infection.